跳至主要内容
临床试验/NCT05643950
NCT05643950撤回不适用

Evaluation of the Efficacy and Cost-effectiveness of the T-Control® Catheter Versus the Foley Type Catheter in Patients With Acute Urinary Retention. Randomized Controlled Pilot Clinical Trial

Rethink Medical SL4 个研究点 分布在 1 个国家开始时间: 2023年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
4
主要终点
Magnitude of infections

研究概览

简要总结

The general purpose of this study is to assess the preliminary effectiveness and cost-effectiveness of the T-Control® catheter versus the Foley type catheter in patients with Acute Urine Retention.

详细描述

Potential participants will be identified by the team of healthcare professionals of the emergency department according to the inclusion and exclusion criteria of the study. If the patient meets the criteria, the emergency department team will be able to refer patients directly to the urology department, where the investigator or research assistant will again check the inclusion and exclusion criteria, will invite the patient or their relative/caregiver (if necessary) to participate in the study and will request their informed consent. The catheter insertion will be carried out by the research staff after the inclusion and randomisation of the participants.

After catheter insertion, participants and their family, friends, or other informal caregivers will receive information about wearing an indwelling urinary catheter and specific information to randomly inserted, standard Foley, or T-Control® catheters. Standard catheter care is permitted during the trial both managed by the participants and participants' caregivers. Additionally, participants will receive an incident diary in which participants can record any type of incident during the bladder catheterisation period. Two weeks after indwelling bladder catheter insertion, participants will be contacted by urology outpatients for a follow-up visit, during which the study catheter will be removed.

Finally, within a maximum period of two weeks after the follow-up visit, the participants will be invited to participate in an interview to assess the quality of life perceived by the participants during the study

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

盲法说明

Data analysis will be blinded to the intervention arm as well as the laboratories that will carry out the analysis of the urine and catheter samples.

入排标准

年龄范围
50 Years 至 100 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Males with Acute Urine Retention
  • Equal or over 50 years of age
  • Absence of symptoms of infection on the inclusion day
  • Not having been previously catheterized on the day of inclusion
  • Indication of bladder catheterization for 2 weeks
  • Maintained cognitive and physical capacity for self-monitoring the catheter valve
  • Signed consent agreement

排除标准

  • Current or recent urinary tract infection in the last 2 weeks
  • Use of current treatment/antibiotic in the last 2 weeks
  • Immunocompromised patients (diagnosed with advance cancer, Acquired Immunodeficiency Syndrome,...)
  • Catheter insertion requiring more than 1 attempt
  • Overactive bladder
  • Patients with bilateral obstructive uropathy

结局指标

主要结局

Magnitude of infections

时间窗: Day 14 after inclusion (follow-up visit)

The magnitude of infection will be obtained from the analysis of urine culture samples taken from participants

次要结局

  • Self-perceived health-related quality of life (HRQoL)(Day 14 after inclusion (follow-up visit))
  • Number of adverse events related to catheterization(Day 14 after inclusion (follow-up visit))
  • Total costs of each type of catheterization (cost-effectiveness) per quality-adjusted life year (QALY) of catheterized participants(Close-out of the study)
  • Determination of the biofilm formed in the catheters(Day 14 after inclusion (follow-up visit))
  • Rate of symptomatic and asymptomatic infections(Day 14 after inclusion (follow-up visit))
  • Indication of antibiotic treatments(Day 14 after inclusion (follow-up visit))
  • Level of satisfaction and workload of health professionals.(Close-out of the study)
  • Acceptability of the T-Control® device(Day 14 after inclusion (follow-up visit))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验